Scilex Holding Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Scilex Holding Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.25M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $56.59M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $46.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $38.03M | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | $31.32M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $23.56M | Mar 7, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $125.80M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $167.40M | Apr 10, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($374.05M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($72.81M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($114.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($23.36M) | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | ($88.42M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | ($6.3K) | Feb 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($346.01M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($83.40M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($105.43M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($50.63M) | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | ($35.84M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | ($6.3K) | Feb 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.71M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $9.64M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $12.75M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.05M | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | $9.20M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $9.96M | Mar 7, 2023 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $266.88M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $119.02M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $119.64M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $64.90M | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | $50.58M | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $42.97M | Mar 7, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.82M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $19.35M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($20.71M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($21.26M) | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | ($28.66M) | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | ($1.3K) | Feb 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.0K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $30.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.0K | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | $0 | Mar 12, 2024 |
| FY2022 | Dec 31, 2020 | $25.0K | Mar 7, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.98M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $92.95M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $101.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $86.53M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $77.93M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $199.5K | Feb 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $576.73M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $285.59M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $274.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $50.29M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $301.81M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $180.8K | Feb 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($207.78M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($192.64M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($172.94M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $36.24M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($223.88M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $18.7K | Feb 24, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.48M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $13.48M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $13.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.48M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $13.48M | Mar 7, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($921.79M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($563.05M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($490.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($375.91M) | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | ($352.55M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($6.3K) | Feb 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.96M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.27M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $3.92M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.18M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | $4.34M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $30.5K | Feb 24, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Mar 7, 2023 |
| FY2022 | Dec 31, 2021 | $72.04M | Mar 7, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (36) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | (7) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (36) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | (8) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 12, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 12, 2024 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.03M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 5.24M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 100.02M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 141.35M | Mar 12, 2024 |
| FY2022 | Dec 31, 2021 | 132.86M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 3.45M | Feb 24, 2022 |